Coni-Snap® Sigma Series Hard Gelatin capsule

Custom inner surface properties, customized moisture levels and more stringent microbial limits all designed to optimize inhalant end-product performance. Available in gelatin, gelatin-PEG, Capsugel® Vcaps® and Capsugel® Vcaps® Plus.

DBcaps® capsules were developed with a tamper-evident design to specifically address the clinical trial challenges of testing without bias. The wider diameter of opaque DBcaps® allows containment and blinding of large-diameter or uniquely-shaped tablets or other comparator products...

Oral solid dosage form with first of its kind enteric manufacturing technology. 
Discover a unique manufacturing process to build a bi-layer capsule to assist in enteric delivery. ​

An optimized tool for formulation development enabling compatibility studies before deciding on the final color for the commercial drug products. Available in gelatin and HPMC.​

Press-Fit® Gelcaps utilize a Capsugel®  technology that is difficult to mimic and enables brands to create a new product look without having to reformulate their product. Flexible gelcaps are stretched around a caplet of specified shape and dimension using a pat...

Designed to be easily opened by patients and caregivers, these capsules are ideal for pediatric and geriatric populations. Available in gelatin and HPMC.​

The reliable and outstanding performance of Coni-Snap® hard gelatin capsules has made them a product of choice for biopharmaceutical companies since their unique locking closure was introduced. Designed and engineered to perform, they are a reliable and widely used capsule.

The global population continues to age, however mobility is no longer just a concern that affects seniors; consumers across the generations are now looking for efficacious products to promote aging well and support peak physical perfomance. Healthy joints play a pivotal role in protecting mobility as w...

Lonza Engine™ offers state-of-the-art equipment designed to address the needs of customers throughout the entire drug development process including:  ​  ​

·         Liquid-filled hard capsules filling and sealing equipment: support fo...

The Capsugel® capsule portfolio provides a wide variety of high-quality products and technologies to help you create a customized solution to bring new innovations to market.

DRcaps® capsules are innovative HPMC capsules that can help protect dietary supplement ingredients from stomach acidity without the cost and complexity of adding acid-resistant properties during manufacturing. DRcaps® capsules can also help mask taste and odor and reduce bad aftertaste without the addition...

At Lonza, we’re driven by our purpose to enable a healthier world. It’s the ‘why’ behind everything we do and it’s the driving force behind our Launch with Lonza™ application lab services. From innovation to commercialization, our multi-disciplinary team brings more than 100 years of combined knowledge to ...

In our packed out content sessions at CPHI Barcelona this year we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field. 

Dry-powder inhalation (DPI) technology offers a favorable drug development opportunity for respiratory or systemic drug delivery. Delivering a uniform dose in a portable, easy-to-use system, capsule-based DPI devices are a simple and cost-effective way to deliver inhalable medication. Capsugel® Zephyr™ is Lonza’s customizable dry-powder inhalation capsule portfolio that is optimized to provide superior performance and compatibility between the capsule/device and capsule/formulation.

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner. 

The Company Showcase profiles offer a library of free to access, downloadable content, including videos and webinars, reports, whitepapers and product brochures, from the Pharma suppliers and service providers you’d look to meet at our events.

A full suite of concept-to-market services to turn ideas into breakthrough products.

Discover the possibilities of TiO2-free white gelatin capsules without sacrificing quality and functionality.

The Capsugel®️ capsule portfolio provides a wide variety of high-quality products and technologies to help you create a customized solution to bring new innovations to market.

Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Without upfront knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs. Physiologically-based pharmacokinetic (PBPK) modeling software, such as the GastroPlus® platform from Simulations Plus, simulates dynamic physiological factors impacting oral performance. When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) assessing the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions to mitigate these risks, and 3) designing and optimizing preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification to maximize the likelihood of achieving desired PK profiles. In this presentation, we will demonstrate how PBPK models combined with Lonza’s custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies. Key Learning Objectives: Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies (e.g. bioavailability enhancement) for early drug candidates. Learn how PBPK modeling coupled with in vitro testing can guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors including solubility, permeability, and dissolution rate can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects.

Explore Lonza new innovation center, dedicated to accelerating capsule development for oral and pulmonary drug delivery. Join us to discover how we foster collaboration with customers and co-innovation in a cutting-edge environment where science meets ingenuity. Learn how our expert team tackles complex formulation challenges, navigates global regulatory requirements, and supports your journey from concept to market. Experience how Lonza can partner with you to redefine the future of pharmaceutical excellence.